Page 1

Agiletines THERAPEUTICS Agile Therapeutics Reports Second Quarter 2021 Financial Results July 26 , 2021 Total Prescriptions ( TRX ) Grew 171 % in Second Quarter Prescribers , New Prescriptions and Refill Rates Continue to Grow in Second Quarter Company Continues to Progress on Expanding Access to Twirla Management to Host Conference Call Today , Monday , July 26 , 2021 at 4:30 p.m. EDT PRINCETON , N.J. , July 26 , 2021 ( GLOBE NEWSWIRE ) -- Agile Therapeutics , Inc. ( Nasdaq : AGRX ) , a women's healthcare company , today reported financial results for the three months ended June 30 , 2021 and provided a corporate update . " The theme of Agile's 2021 second quarter is growth . We believe we have the building blocks in place for continued growth and we remain on track to achieve our near - term goal of establishing Twirla in the $ 4.1B U.S. hormonal contraceptive market , " said Chairman and Chief Executive Officer Al Altomari . " We have an approved product that is growing in all major prescription performance areas and we believe we are only scratching the surface as we unleash more direct - to - consumer advertising and further develop the channels that provide women access to Twirla . " Recent Corporate Developments and Second Quarter 2021 Results : Twirla Performance and Updates • During the second quarter 2021 , total prescriptions were 5,027 , representing an increase of 171 % from the end of the first quarter . New prescriptions were 2,857 and grew by 103 % over the same period . The growth was driven by an increase in the number of prescribers , which as of June 30 , 2021 was more than 2,087 healthcare providers ( HCPs ) , and growing refill rates . As of June 30 , 2021 , 2,033 prescriptions dispensed at pharmacies were refills , which represented an increase of 355 % during the second quarter . The Company also saw an increase in the number of total prescriptions by prescriber . • Twirla is now available to Medicaid patients in approximately 75 % of states either through traditional Medicaid and / or managed Medicaid . With these new additions , Twirla now has coverage in approximately 50 % of the total Medicaid transdermal TRX market with no restrictions . Overall , Twirla has access in approximately 55 % of the commercial and government CHC market based on claims . • In addition to progress on Medicaid and Managed Care access , the Company also saw expanded access through state clinics , where there was significant non - retail prescription volume in the second quarter . Marketing Campaign Updates • The Company increased its incremental branded consumer marketing investment quarter over quarter in the second quarter , and Twirla's advertising presence on dating apps such as Tinder and OK Cupid exceeded expectations in less than a month . • The Company believes that as more women in the target audience gain exposure to Twirla through branded advertising efforts , Twirla prescriptions will continue to grow . Second Quarter 2021 Financial Results • Net revenue : The Company delivered $ 1.2 million in net product sales revenue in the second quarter . • Cost of product revenues : The cost of product revenues for the quarter ended June 30 , 2021 was $ 1.1 million which included direct and indirect expenses supporting our manufacturing and distribution efforts , including personnel costs and approximately $ 500,000 of non - cash depreciation expense . The Company expects these relatively fixed costs to become less significant as a percentage of sales with anticipated volume increases . Until May of 2021 , the Company was selling units from validation batches that had no associated product cost as the cost had been previously expensed . Approximately 76 % of the units sold in the second quarter had associated product cost . All future sales of product will have an associated product cost .